Evaluating anti‑tumor activity of palbociclib plus radiation in anaplastic and radiation‑induced meningiomas: pre‑clinical investigations

• A. Das ^[1] ; M. Alshareef ^[1] ; J. L. Martinez Santos ^[1] ; G. B. F. Porto ^[1] ; D. G. McDonald ^[1] ; L. K. Infinger ^[1] ; W. A. Vandergrift III ^[1] ; S. M. Lindhorst ^[1] ; A. K. Varma ^[1] ; S. J. Patel ^[1] ; D. Cachia ^[1]
  1. [1] Medical University of South Carolina

     Medical University of South Carolina

     Estados Unidos

     
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 22, Nº. 11, 2020, págs. 2017-2025
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Purpose Meningiomas are common brain tumors, the majority of which are considered benign. Despite surgery and/or radia-tion therapy, recurrence rates are approximately 8–10%. One likely cause is the dysregulation of cyclin d-cyclin-dependent kinases 4 and 6 (CDK4/6)-retinoblastoma (Rb) pathway, which controls the cell cycle restriction point. This pathway is commonly dysregulated in anaplastic meningioma cell lines (AM) and radiation-induced meningioma cells (RIM), making it a rational target for anti-meningioma therapy. In this study, we investigate the effect of a CDK4/6 inhibitor, palbociclib, with radiation in relevant pre-clinical models.MethodsIn vitro cell culture, ex vivo slice culture and in vivo cell line-derived orthotopic xenograft animal models of AM/RIM were utilized to assess treatment efficacy with palbociclib plus radiation. Treatment effects were examined by immu-noblot, cell viability, apoptosis, and cell cycle progression.ResultsThe in vitro and ex vivo studies demonstrate that palbociclib plus radiation treatment reduced proliferation and has additional effects on cell cycling, including induction of an RB-associated G (1) arrest in Rb+ AM and RIM cells, but not in Rb− cells. Our results also demonstrated reduced CDK4 and CDK6 expression as well as reduced E2F target gene expres-sion (CCNA2 and CCNE2) with the combination therapy. MRI results in vivo demonstrated reduced tumor size at 5 weeks when treated with 14 days palbociclib (10 mg/kg) plus 6 Gy radiation compared to saline-treated tumors. Finally, no hepatic toxicity was found after treatments.Conclusion A pre-clinical murine model provides preclinical evidence for use of palbociclib plus radiation as a therapeutic agent for Rb+ meningiomas.